Human ACE2 (multimeric) (18-652) Recombinant Protein #85054
Supporting Data
| MW (kDa) | 96 (reduced) |
Product Information
Formulation
Expression Host: Human (HEK293-EBNA cells)
Supplied in a PBS solution.
Supplied in a PBS solution.
Storage
Stable at -80°C for 3 years after receipt. Avoid repeated freeze-thaw cycles.
Product Description
Human ACE2 (multimeric) (18-652) Recombinant Protein is a fusion protein containing an exogenous oligomerization domain, enabling expression of Human ACE2 as a multimer. The multimeric form provides increased binding avidity (relative to monomeric ACE2 protein) to recombinant protein corresponding to the SARS-CoV-2 receptor binding domain (RBD). Human ACE2 (multimeric) (18-652) Recombinant Protein may be biotinylated using the Avitag™ system.
| MW (kDa) | 96 (reduced) |
| Purity | 93%, determined by SDS-PAGE. |
Background
ACE2 is a carboxypeptidase that catalyses the conversion of angiotensin I to angiotensin 1-9, or of angiotensin II to the vasodilator angiotensin 1-7 (1). ACE2 is a critical component in the renin-angiotensin system (RAS). ACE2 is predominantly expressed in vascular endothelial cells of the heart and kidney and Leydig and Sertoli cells of the testis (2,3). The unique expression pattern of ACE2 determines its essential role in the regulation of cardiovascular and kidney functions, as well as fertility. ACE2 protein is localized mainly in the extracellular space with its carboxy terminal end attached to the membrane via its transmembrane domain. Active ACE2 enzyme is secreted by cleavage at the amino terminus. Research studies have shown that ACE2 expression is elevated in human failing heart (4). ACE2 has also been identified as the receptor for SARS and SARS-CoV-2 coronaviruses (5-7).
- Schmidt, B.L. et al. (2000) J Clin Microbiol 38, 1279-82.
- Boehm, M. and Nabel, E.G. (2002) N Engl J Med 347, 1795-7.
- Douglas, G.C. et al. (2004) Endocrinology 145, 4703-11.
- Goulter, A.B. et al. (2004) BMC Med 2, 19.
- Li, W. et al. (2005) EMBO J 24, 1634-43.
- Hoffmann, M. et al. (2020) Cell 181, 271-280.e8.
- Lan, J. et al. (2020) Nature 581, 215-20.
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意，否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件，除非书 CST 的合法授书代表以书面形式书独接受， 否书均被拒书，并且无效。
专品专有“专供研究使用”的专专或专似的专专声明， 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的， 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专，且专用于研专用途。将专品用于专断、专防或治专目的， 或专专售（专独或作专专成）或其他商专目的而专专专品，均需要 CST 的专独专可。客专：(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品，或使用专品制造任何商专专品，(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专，或使用专品开专任何与 CST 的专品或服专专争的专品或服专， (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专，(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品， (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专
For Research Use Only. Not for Use in Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
All other trademarks are the property of their respective owners. Visit our
Trademark Information page.